Wegovy at BMI 29: What the Licence Actually Says

The misconception: BMI 29 automatically rules you out

The most common misreading of Wegovy's licence is that it kicks in only at BMI 30 and higher, making BMI 29 a closed door. That reading is wrong, and it stops some people from even asking. The licensed indication for semaglutide (Wegovy) (as confirmed by the MHRA and reflected in NICE's appraisal of semaglutide for weight management (TA875)) covers adults with a BMI of 27 or above, provided a weight-related health condition is also present. A BMI of 29 sits squarely in that band.

The condition requirement is the part people miss. High blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea, and established cardiovascular disease are the conditions most commonly considered. If you have one of those and a BMI of 29, eligibility becomes a real conversation rather than a non-starter. It is worth sitting with that for a moment if you have spent time assuming this option was not available to you.

It is also worth knowing that BMI thresholds are set 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, meaning a threshold of around 24.5 or 27.5 may apply depending on the category, rather than the standard 27 or 30, and what that lower BMI threshold means for Wegovy eligibility is worth reading if that adjustment could apply to you. How the 27–29.9 range works in practice covers this in more detail.

What the comorbidity requirement actually means at BMI 29

Having a comorbidity on paper is necessary but not the whole story. The prescriber is not simply ticking a box; they are assessing whether the clinical risk from your weight-related condition is meaningful and whether Wegovy is appropriate given your broader health profile. Someone with mild borderline hypertension managed entirely by lifestyle may face a different conversation to someone with confirmed hypertension on medication.

The conditions that most straightforwardly satisfy the requirement include diagnosed and treated hypertension, dyslipidaemia (elevated LDL or triglycerides), type 2 diabetes or prediabetes, obstructive sleep apnoea confirmed by sleep study, and documented cardiovascular disease. Some prescribers may consider other metabolic conditions; it depends on clinical judgement. The NHS medicines page for semaglutide sets out the licensed uses clearly and is a good reference before your consultation.

One practical point: if you are close to BMI 30 and do not have a clear comorbidity, a straightforward BMI of 30 or above unlocks eligibility without that additional requirement. Eligibility at BMI 30 explains what changes at that threshold and why the distinction in the licence exists.

How private and NHS eligibility differ at BMI 29

The NHS route for Wegovy operates under NICE TA875, which requires access through a specialist weight management service and sets its own BMI criteria, typically BMI 35 or above with at least one comorbidity for standard-threshold patients, with lower figures applying for some ethnic backgrounds. That means BMI 29 does not currently meet NHS criteria regardless of comorbidities, and waiting lists for specialist services are long in most areas.

Private prescription, through a regulated online pharmacy like ours, follows the medicine's licensed indication rather than the NICE commissioning threshold. That is why BMI 29 with a qualifying condition is a genuine route privately, even though it is not on the NHS. There is no referral needed and no waiting list; the assessment happens with a prescriber directly. If you are weighing up the cost side of things, our treatment overview explains what private weight management treatment through nume actually involves. Every repeat order is clinically re-reviewed, there is no subscription that runs on automatically.

For context on how the 2.5 kg/m² ethnic-background adjustment works across the BMI range, the BMI you need to take Wegovy covers the full picture in one place.

What happens during the clinical assessment at BMI 29

If you start a consultation at BMI 29, the prescriber's first question (in effect) is whether a qualifying condition is confirmed and documented. They will also look at your broader health: any medicines you already take, relevant history (pancreatitis, gallbladder disease, thyroid conditions, pregnancy or plans to conceive all affect suitability), and whether your weight-management goals are realistic and safely pursued with Wegovy. A prescriber who does not know you will rely on the information you provide and, where appropriate, on your Summary Care Record.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the day you submit it. The prescriber decides suitability; this is not an automated process. Identity is verified by photo ID, and weight is verified on a live video call. If the prescriber approves treatment, dispatch happens the same day for orders placed before noon, with free next-working-day tracked delivery. Getting Wegovy online safely walks through what that process looks like end to end.

If you are not sure whether your BMI and health profile make you a candidate, the consultation itself is the right place to find out. There is no charge for it, and a genuine clinical assessment is the only way to get a reliable answer. Start your free consultation and our prescribers will review your situation properly.